Kopran Q1 FY27: consolidated PAT -10% YoY as subsidiaries swing to loss; standalone +91%

Kopran's consolidated Q1 FY27 (quarter ended June 30, 2026) results show revenue of ₹153.99 Cr, up 13.9% YoY (down 34.2% QoQ against a much stronger ₹234.02 Cr Q4 FY26 base), but consolidated PAT fell 10.0% YoY to ₹6.70 Cr (down 64.5% QoQ from ₹18.87 Cr) — EPS ₹1.39 versus ₹1.54 a year ago. No exceptional items feature in either period, so the decline sits on a clean base. No analyst consensus or brokerage preview could be found for this specific quarter (small/mid-cap coverage is thin), so vs-street is unknown; the company also carries no formal guidance on record for this print, so vs-guidance is unknown as well — management gives no stated outlook in the filing itself. The consolidated decline masks a sharp divergence from the standalone (parent, India manufacturing) business: standalone revenue grew 22.3% YoY to ₹62.76 Cr and standalone PAT surged 91.1% YoY to ₹6.72 Cr (from ₹3.52 Cr) — standalone PAT alone now accounts for essentially all of consolidated PAT, versus contributing only ~47% of it a year ago. The swing is entirely a subsidiary-level story: consolidated PAT less standalone PAT works out to a roughly ₹0.02 Cr net drag this quarter, versus a ~₹3.93 Cr positive contribution from subsidiaries (Kopran Research Laboratories, Kopran Lifesciences, Kopran (H.K.) and Kopran (UK)) in Q1 FY26. The auditors' consolidated review report separately notes that two subsidiaries reviewed by other auditors posted a combined net loss of ₹26.13 Lakhs on total income of ₹100.18 Cr for the quarter, with two further unreviewed subsidiaries posting a marginal ₹1.23 Lakh loss — consistent with the subsidiary base turning loss-making after being profitable a year earlier. On margins, consolidated NPM compressed to 4.35% from 5.41% a year ago (Q4 FY26 was 8.06%), while OPM was roughly flat at ~10.26% versus 10.45% YoY but well below Q4 FY26's 14.08%. The pressure sits mainly on the cost line: consolidated cost of materials consumed jumped 50.5% YoY to ₹120.89 Cr, well ahead of the 13.9% revenue growth, pushing the raw-material ratio to 78.5% of revenue from 59.4% a year ago. Finance costs rose 29.3% YoY to ₹3.28 Cr and depreciation rose 35.5% YoY to ₹5.77 Cr, both consistent with a growing asset/debt base, adding drag below the operating line even as the standalone business scaled well. Total consolidated expenses grew 15.1% YoY, outpacing the 13.9% revenue increase. Corporate activity this quarter includes a ₹3.00/share dividend declared alongside FY26 results on May 19, 2026 (record date August 11, 2026), the appointment of Vijay L. Thange as Chief Technical Officer (June 26, 2026), the 67th AGM held around July 25, 2026, and a rights issue in a subsidiary alongside a new subsidiary director appointment (May 18, 2026) — the rights issue may be a lever to recapitalise a subsidiary base that has just turned loss-making. No management press release or concall commentary accompanies this filing, so there is no company framing to reconcile against the numbers. Going into Q2 FY27, the print sets up two threads to watch: whether the standalone business's strong growth (+91% PAT YoY) continues, and whether the subsidiaries' swing to a loss was a one-off or a trend that keeps dragging consolidated numbers below the parent's underlying performance.